Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 75 years old.
- Your leukemia is B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatment, and it has at least 5% blasts in your bone marrow or blood.
- Your leukemia cells must test positive for CD19 or CD20 (or both) markers.
- You must not have active infections like HIV, syphilis, active hepatitis B or C, or any other uncontrolled active infection.
- You must not have had a stem cell transplant in the last 12 weeks, or a donor lymphocyte infusion in the last 6 weeks.
- You must have adequate organ function (kidney, liver, heart, lungs) and be willing to use very effective birth control for one year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL). The treatment takes your own immune cells, changes them to fight cancer, and then gives them back to you. The goal is to kill leukemia cells and help you go into remission.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
This trial tests a new type of immunotherapy called CAR-T-19 for children and young adults up to age 25 whose B-ALL has returned or is not responding to standard treatments. The CAR-T cells are engineered to find and destroy leukemia cells that have the CD19 protein.
Hear when a new ALL (Acute B-Lymphoblastic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.